Target Name: MIR3690
NCBI ID: G100500894
Review Report on MIR3690 Target / Biomarker Content of Review Report on MIR3690 Target / Biomarker
MIR3690
Other Name(s): mir-3690-2 | microRNA 3690 | hsa-mir-3690-1 | MicroRNA 3690 | MIR3690-2 | hsa-miR-3690 | MIR3690-1 | mir-3690-1 | hsa-mir-3690-2

MIR3690: A Potential Drug Target and Biomarker

Molecular Targets and Biomarkers

MIR3690 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of cytoskeletal proteins, known as the myosin regulatory protein (Myosin) family 3. MIR3690 is unique due to its unique structure and function.

The Myosin Regulatory Protein (Myosin) Family 3

Myosin regulatory proteins (Myosin) are a family of proteins that play a critical role in muscle contraction and relaxation. They are involved in many different cellular processes in the body, including the regulation of cell growth, differentiation, and survival. Myosin regulatory proteins are divided into several subfamilies, including Myosin regulatory protein (Myosin), Myosin light chain protein (Myql), Myosin heavy chain protein (Myh), and Myosin interacting protein (Mip).

MIR3690 is a member of the Myosin regulatory protein (Myosin) family 3. It is characterized by a unique structure that includes a catalytic domain, a nucleotide-binding domain (NBD), and a carboxy-terminal domain (CTD). The NBD and CTD are responsible for the protein's stability and function, respectively.

MIR3690's Unique Structure and Function

MIR3690's unique structure and function are what make it an attractive drug target and biomarker. The NBD and CTD of MIR3690 are involved in its stability and function. The NBD helps to maintain the protein's stability, while the CTD is involved in its interaction with other proteins.

MIR3690's NBD is a key structural element that helps to maintain its stability. The NBD is composed of a unique ionic pair that includes a negatively charged calcium ion (Ca2+) and a negatively charged phosphate ion (PO43-). This ionic pair helps to maintain the protein's stability by neutralizing the negatively charged phosphate ion, which can otherwise cause the protein to become phosphorylated and unstable.

MIR3690's CTD is also an important structural element that helps to maintain its stability. The CTD includes a unique acidic amino acid residue (Asp221) that is involved in the protein's interaction with other proteins. This acidic amino acid residue helps to form a hydrogen bond with other negatively charged residues in the protein, which can help to maintain its stability.

MIR3690's Structure and Function in Disease

MIR3690's unique structure and function have been implicated in several diseases. One of the most well-studied diseases associated with MIR3690 is cancer. Cancer cells have been shown to alter the expression and stability of MIR3690. For example, studies have shown that MIR3690 is overexpressed in many types of cancer, and that its expression is associated with cancer cell survival and proliferation.

Another disease associated with MIR3690 is neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. MIR3690 has been shown to be involved in the regulation of neurotransmitter release from neurons, which is important for the proper functioning of the brain. Studies have shown that MIR3690 is expressed in the brains of individuals with Alzheimer's disease and Parkinson's disease, and that its expression is altered in these conditions.

MIR3690 as a Drug Target

MIR3690's unique structure and function make it an attractive drug target. Studies have shown that MIR3690 is involved in a wide range of cellular processes, including

Protein Name: MicroRNA 3690

The "MIR3690 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR3690 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR3691 | MIR3692 | MIR370 | MIR3713 | MIR3714 | MIR371A | MIR371B | MIR372 | MIR373 | MIR374A | MIR374B | MIR374C | MIR375 | MIR376A1 | MIR376A2 | MIR376B | MIR376C | MIR377 | MIR378A | MIR378B | MIR378C | MIR378D1 | MIR378D2 | MIR378E | MIR378F | MIR378G | MIR378H | MIR378I | MIR379 | MIR380 | MIR381 | MIR382 | MIR383 | MIR384 | MIR3907 | MIR3908 | MIR3909 | MIR3910-1 | MIR3910-2 | MIR3911 | MIR3912 | MIR3913-1 | MIR3913-2 | MIR3914-1 | MIR3914-2 | MIR3915 | MIR3916 | MIR3917 | MIR3918 | MIR3919 | MIR3920 | MIR3921 | MIR3922 | MIR3923 | MIR3924 | MIR3925 | MIR3926-1 | MIR3926-2 | MIR3927 | MIR3928 | MIR3929 | MIR3934 | MIR3935 | MIR3936 | MIR3936HG | MIR3937 | MIR3938 | MIR3939 | MIR3940 | MIR3941 | MIR3942 | MIR3943 | MIR3944 | MIR3945 | MIR3945HG | MIR3960 | MIR3972 | MIR3973 | MIR3974 | MIR3976 | MIR3976HG | MIR3977 | MIR3978 | MIR409 | MIR410 | MIR411 | MIR412 | MIR421 | MIR422A | MIR423 | MIR424 | MIR425 | MIR4251 | MIR4252 | MIR4253 | MIR4254 | MIR4255 | MIR4256 | MIR4257 | MIR4258